Evidence map›Paper›PMID 29520276›Full record

ArticleFrontiers in immunology2018

Alloreactive T Cell Receptor Diversity against Structurally Similar or Dissimilar HLA-DP Antigens Assessed by Deep Sequencing.

Esteban Arrieta-Bolaños, Pietro Crivello, Maximilian Metzing, Thuja Meurer, Müberra Ahci, Julie Rytlewski, Marissa Vignali, Erik Yusko, Peter van Balen, Peter A Horn and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. The Pursuit of Regulatory T Cells in the Induction of Transplant Tolerance.Advances in experimental medicine and biology · 2021
    Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Esteban Arrieta-BolañosInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Pietro CrivelloInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Maximilian MetzingInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Thuja MeurerInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Müberra AhciInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Julie RytlewskiAdaptive Biotechnologies, Seattle, WA, United States.
Marissa VignaliAdaptive Biotechnologies, Seattle, WA, United States.
Erik YuskoAdaptive Biotechnologies, Seattle, WA, United States.
Peter van BalenDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Peter A HornInstitute for Transfusion Medicine, University Hospital Essen, Essen, Germany.
J H Frederik FalkenburgDepartment of Hematology, Leiden University Medical Center, Leiden, Netherlands.
Katharina FleischhauerInstitute for Experimental Cellular Therapy, University Hospital Essen, Essen, Germany.
Essen University Hospital · DEAdaptive Biotechnologies (United States) · USLeiden University Medical Center · NLGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

T cell alloreactivity is mediated by a self-human leukocyte antigen (HLA)-restricted T cell receptor (TCR) repertoire able to recognize both structurally similar and dissimilar allogeneic HLA molecules (i.e., differing by a single or several amino acids in their peptide-binding groove). We hypothesized that thymic selection on self-HLA molecules could have an indirect impact on the size and diversity of the alloreactive response. To test this possibility, we used TCR Vβ immunophenotyping and immunosequencing technology in a model of alloreactivity between self-HLA selected T cells and allogeneic HLA-DPB1 (DPB1) differing from self-DPB1*04:02 by a single (DPB1*02:01) or several (DPB1*09:01) amino acids in the peptide-binding groove. CD4+ T cells from three different self-DPB1*04:01,*04:02 individuals were stimulated with HeLa cells stably transduced with the relevant peptide processing machinery, co-stimulatory molecules, and HLA-DP. Flow cytometric quantification of the DPB1-specific T cell response measured as upregulation of the activation marker CD137 revealed significantly lower levels of alloreactivity against DPB1*02:01 compared with DPB1*09:01 (mean CD4+CD137+ frequency 35.2 ± 9.9 vs. 61.5 ± 7.7%, respectively,

Indexed as

AllelesAutoantigensCD4-Positive T-LymphocytesClonal Selection, Antigen-MediatedGenetic VariationHeLa CellsHigh-Throughput Nucleotide SequencingHLA-DP AntigensHumansImmunophenotypingIsoantigensReceptors, Antigen, T-Cell, alpha-betaAutoantigensHLA-DP AntigensIsoantigensReceptors, Antigen, T-Cell, alpha-betahuman leukocyte antigen-DPB1next-generation sequencingpermissive mismatchesT-cell alloreactivityT-cell receptor repertoire

Identifiers

PMID29520276
PMCPMC5827552
OpenAlexW2789336815

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.